Neuroleptic malignant syndrome precipitated by haloperidol following clozapine discontinuation.
Mendhekar
D N
DN
Jiloha
R C
RC
D000328:Adult; D014151:Anti-Anxiety Agents / Q000008:administration & dosage; D000978:Antiparkinson Agents / Q000008:administration & dosage; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001971:Bromocriptine / Q000008:administration & dosage; D003024:Clozapine / Q000009:adverse effects*; D003402:Creatine Kinase / Q000097:blood / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004565:Electroconvulsive Therapy / Q000379:methods; D006220:Haloperidol / Q000009:adverse effects*; D006801:Humans; D008140:Lorazepam / Q000008:administration & dosage; D008297:Male; D009459:Neuroleptic Malignant Syndrome / Q000150:complications* / Q000188:drug therapy / Q000523:psychology; D011618:Psychotic Disorders / Q000150:complications / Q000188:drug therapy; D012559:Schizophrenia / Q000188:drug therapy; D013375:Substance Withdrawal Syndrome / Q000150:complications* / Q000188:drug therapy / Q000523:psychology
D014151:Anti-Anxiety Agents; D000978:Antiparkinson Agents; D014150:Antipsychotic Agents; D001971:Bromocriptine; D003402:Creatine Kinase; D003024:Clozapine; D006220:Haloperidol; D008140:Lorazepam